For the quarter ending 2026-01-31, ANIX has $15,233K in assets. $1,387K in debts. $1,547K in cash and cash equivalents.
| Balance Sheets | 2026-01-31 | 2025-10-31 | 2025-07-31 | |
|---|---|---|---|---|
| Receivables | - | - | 0 | |
| Cash and cash equivalents | 1,547 | 1,244 | 1,495 | |
| Short-term investments | 12,655 | 13,930 | 14,534 | |
| Prepaid expenses and other current assets | 848 | 713 | 1,420 | |
| Total current assets | 15,050 | 15,887 | 17,449 | |
| Operating lease right-of-use asset | 183 | 193 | 202 | |
| Total assets | 15,233 | 16,080 | 17,651 | |
| Accounts payable | 148 | 165 | 276 | |
| Accrued expenses | 1,046 | 1,761 | 1,751 | |
| Operating lease liability | 42 | 41 | 39 | |
| Total current liabilities | 1,236 | 1,967 | 2,066 | |
| Operating lease liability, non-current | 151 | 163 | 174 | |
| Total liabilities | 1,387 | 2,130 | 2,240 | |
| Preferred stock, value | - | - | 0 | |
| Preferred stock, value-Series AConvertible Preferred Stock | - | - | 0 | |
| Treasury stock, 2,000 shares at cost as of october 31, 2024 | - | - | 0 | |
| Common stock, par value .01 per share 100,000,000 shares authorized 33,463,440 and 33,013,829 shares issued and outstanding as of january 31, 2026 and october 31, 2025, respectively | 335 | 330 | 328 | |
| Additional paid-in capital | 268,984 | 266,508 | 265,249 | |
| Accumulated deficit | -254,242 | -251,677 | -248,982 | |
| Total shareholders equity | 15,077 | 15,161 | 16,595 | |
| Noncontrolling interest (note 2) | -1,231 | -1,211 | -1,184 | |
| Total equity | 13,846 | 13,950 | 15,411 | |
| Total liabilities and equity | 15,233 | 16,080 | 17,651 | |
Anixa Biosciences Inc (ANIX)
Anixa Biosciences Inc (ANIX)